1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

 
• By Sue Sutter

US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.

Casting net
Sponsors need to cast a wider net when consulting patient advocacy and community-based organizations for help on clinical trial diversity plans. • Source: Shutterstock

The US Food and Drug Administration wants to see more diversity in the patient advocacy groups and community organizations with which biopharma sponsors engage as they develop and implement clinical trial diversity plans.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D